NGD 913

Drug Profile

NGD 913

Alternative Names: CP 615003; NGD 91-3

Latest Information Update: 12 Aug 2008

Price : $50

At a glance

  • Originator Neurogen Corporation; Pfizer
  • Class Anxiolytics
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 07 Jan 2002 A study has been added to the adverse events and Anxiety Disorders therapeutic trials sections
  • 04 Dec 2000 Phase-II clinical trials for Anxiety disorders in USA (Unknown route)
  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top